TY - JOUR
TI - Curative surgery in highly selected patients with heavily pretreated, relapsed/refractory classical Hodgkin lymphoma
AU - Papadakis, V.
AU - Efstathopoulou, M.
AU - Angelopoulou, M.K.
AU - Tsourouflis, G.
AU - Prassopoulos, V.
AU - Rondogianni, P.
AU - Kourtesis, A.
AU - Polychronopoulou, S.
AU - Pangalis, G.A.
AU - Vassilakopoulos, T.P.
JO - Clinical Lymphoma Myeloma and Leukemia
PY - 2021
VL - 62
TODO - 3
SP - 722-726
PB - Taylor and Francis Ltd.
SN - null
TODO - 10.1080/10428194.2020.1842404
TODO - alemtuzumab;  bleomycin;  carmustine;  cisplatin;  cyclophosphamide;  cytarabine;  dacarbazine;  doxorubicin;  etoposide;  gemcitabine;  ifosfamide;  melphalan;  methylprednisolone;  prednisolone;  prednisone;  procarbazine;  programmed death 1 ligand 1;  rituximab;  vinblastine;  vincristine;  vinorelbine tartrate, adolescent;  adult;  anaplastic large cell lymphoma;  autologous stem cell transplantation;  cancer combination chemotherapy;  cancer patient;  cancer radiotherapy;  cancer recurrence;  cancer staging;  cancer surgery;  cancer survival;  case report;  classical Hodgkin lymphoma;  clinical article;  clinical practice;  disease course;  drug megadose;  female;  follow up;  histopathology;  human;  human tissue;  Letter;  long term care;  lumpectomy;  lung adenocarcinoma;  lung cancer;  male;  maximum standardized uptake value;  mediastinum;  medical history;  minimal residual disease;  multiple cycle treatment;  outcome assessment;  overall survival;  positron emission tomography-computed tomography;  priority journal;  recurrent disease;  relapse;  second cancer;  surgical margin;  thymoma;  thyroid cancer;  treatment failure;  watchful waiting;  Hodgkin disease;  nonhodgkin lymphoma, Hodgkin Disease;  Humans;  Lymphoma, Non-Hodgkin
TODO - null
ER -